Mindray (300760) Report Interpretation

Overview

JPMorgan reviews Mindray's stronger-than-expected 2Q26 results and argues that the quarter provides evidence that the domestic downturn has passed. The report maintains an Overweight rating and a Dec-2026 Rmb220 target price, while emphasizing that management commentary on the durability of the China recovery remains important for a meaningful valuation re-rating.

Core views

Mindray reported a better-than-expected 2Q26, with revenue of Rmb9.4bn, up 10% YoY, and adjusted net profit of Rmb2.3bn, up 3% YoY. Both figures exceeded JPMorgan's expectations: it had expected low-single-digit sales growth and a low-single-digit adjusted-profit decline. The key change was China operations returning to growth: China sales rose 9% YoY in 2Q26 after declining 11% YoY in 1Q26. JPMorgan views this reversal as evidence that the domestic recovery is gaining traction. The report identifies China IVD as an important source of the domestic improvement, with IVD revenue rising 10% YoY in 2Q26. Management had indicated in 1Q26 that the worst was over, and JPMorgan believes the latest results support that assessment. It expects consensus to raise FY26E estimates. However, the institution says investors will need more detail from management on the recovery trend and its sustainability before assigning a meaningful valuation re-rating. Overseas demand remained resilient, with international revenue up 12% YoY in 2Q26. Within overseas operations, Patient Monitoring and Life Support grew about 8% YoY and Medical Imaging about 6% YoY. These rates were slower than their respective 15% and 10% growth in 1Q26, but JPMorgan still characterizes overseas growth as on track and sees international expansion as a support for medium- to long-term growth. Profitability was affected by foreign-exchange losses and modest margin pressure. The 2Q26 adjusted net margin was 26.5%, about 1 percentage point below 2Q25, reflecting a 0.9 percentage-point YoY decline in gross margin and a Rmb574mn foreign-exchange loss. On a constant-exchange-rate basis, management said 1H26 adjusted net profit rose 11%, above the 8% sales-growth rate. JPMorgan similarly noted that the earlier 1Q26 profit decline was substantially distorted by FX and tax effects; excluding those effects, 1Q26 net profit fell 4.9% YoY, indicating that core operating performance was stronger than the headline result suggested. JPMorgan considers the recent weakness cyclical rather than structural. It expects China revenue to return to growth in 3Q and retains a positive medium- to long-term view supported by international expansion, IVD automation and high growth in emerging businesses. At the same time, it reduced its medium- to long-term sales-growth trajectory by 1-2 percentage points to low-teens growth because it now assumes a somewhat weaker domestic-market growth backdrop than previously expected. The institution expects the earnings release itself to be positive for the share price, estimating a potential 5-10% gain because a China recovery is now visible and overseas growth remains intact. Its Dec-2026 Rmb220 price target is based on a DCF valuation using a 3.8% risk-free rate, 6.2% market-risk premium, 1.0 beta, 10.0% WACC and 3.0% terminal growth rate. The WACC equals the assumed cost of equity because Mindray has minimal debt.

Analysis framework

JPMorgan compares reported quarterly revenue and adjusted profit with its prior expectations, then traces the result through China and overseas sales trends, including IVD, patient monitoring and imaging. It adjusts interpretation of earnings for foreign-exchange and tax effects, assesses the recovery's likely durability, revises its medium- to long-term sales-growth assumption, and values the company using a discounted-cash-flow framework.

Methodology notes

• Valuation methodsDCF (Discounted Cash Flow)

  Discounted cash flow valuation

  JPMorgan derives its Dec-2026 Rmb220 target price by discounting forecast cash flows and terminal value using a 10.0% WACC and a 3.0% terminal growth rate.

• Quantitative, Factor, and Portfolio TheoryCAPM (Capital Asset Pricing Model)

  Cost of equity based on risk-free rate, market-risk premium and beta

  The report uses a 3.8% China 10-year government-bond yield, a 6.2% market premium and a beta of 1.0 to set a 10.0% cost of equity, which also serves as WACC because Mindray has minimal debt.

• Industry AnalysisVolume-price decomposition

  Segmented growth analysis across domestic and overseas businesses

  The report separates China, overseas, IVD, patient-monitoring and imaging growth to identify the domestic recovery and assess the resilience and pace of international demand.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Mindray-A (300760.SZ, 300760 CH)

  Primary covered company; China recovery and resilient overseas demand underpin JPMorgan's positive view.

  Strengths

  China sales returned to growth, China IVD grew 10% YoY, and overseas revenue rose 12% YoY.

  Weaknesses

  JPMorgan lowered its medium- to long-term sales-growth trajectory by 1-2 percentage points to low-teens growth because of a lower assumed domestic-market growth rate.

  Comparison

  2Q26 China sales growth of 9% YoY contrasts with an 11% YoY decline in 1Q26; overseas PMLS and Medical Imaging growth slowed from 15% and 10% in 1Q26 to about 8% and 6%.

  Risks

  Potential China VBP ASP pressure, product-development delays or failures, overseas-expansion risk, post-M&A integration risk, FX risk, delayed purchases and reputational risk.

Key data

• 2Q26 revenueRmb9.4bnUp 10% YoY; above JPMorgan's expectation of low-single-digit growth.
• 2Q26 adjusted net profitRmb2.3bnUp 3% YoY; above JPMorgan's expectation of a low-single-digit YoY decline.
• China sales growth9% YoYReversed from an 11% YoY decline in 1Q26.
• Overseas sales growth12% YoYDemand remained resilient in 2Q26.
• China IVD growth10% YoYA key contributor to the domestic-business recovery.
• 2Q26 adjusted net margin26.5%About 1 percentage point below 2Q25, affected by a 0.9 percentage-point gross-margin decline and a Rmb574mn FX loss.
• Constant-currency 1H26 adjusted net-profit growth11%Management's figure; above 1H26 sales growth of 8%.
• Dec-2026 target priceRmb220Derived from DCF using a 10.0% WACC and 3.0% terminal growth rate.

Impact & implications

JPMorgan believes the 2Q26 result strengthens the case that Mindray's domestic weakness was cyclical and that a China recovery is beginning to appear in reported numbers. It expects upward pressure on FY26E consensus estimates and improved sentiment, but considers management's evidence on the durability of the recovery necessary for a meaningful re-rating.

Risks

• Potential ASP pressure from China's volume-based procurement program could pressure pricing.
• New-product development delays or failures could weaken growth.
• Overseas operations and market-expansion execution present risks.
• Post-merger-and-acquisition integration could create execution risk.
• Exchange-rate movements could affect earnings.
• Anti-corruption campaign activity in China could delay purchases.
• Product quality, safety, regulatory-compliance or data-security events could damage reputation, customer trust and financial performance.

What to watch

• Management's commentary on the sustainability and trajectory of the China recovery.
• Whether domestic revenue returns to growth in 3Q.
• The pace of China IVD growth and the durability of overseas demand.
• Potential FY26E consensus estimate revisions following the earnings beat.